Multiple drug prescribing by general practitioners in a German region: Implications for drug interactions and patient safety

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 11, 2006, Pages 539-547

  Fux, R ^a   Greiner, D ^a   Geldmacher, M ^b   Morike K ^a   Gleiter, Christoph H ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Health Insurance Medical Service MDK Baden Württemberg   (Germany)

Author keywords

Adverse drug reaction; Drug interaction; Guidelines; Prescriptions; Safety

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMANTADINE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; COTRIMOXAZOLE; DIGITALIS GLYCOSIDE; DIURETIC AGENT; ERGOTAMINE DERIVATIVE; FIBRIC ACID DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERICUM PERFORATUM EXTRACT; IMMUNOSUPPRESSIVE AGENT; LAXATIVE; MACROLIDE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OPIATE; PARACETAMOL; QUINOLINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SULFONYLUREA; THEOPHYLLINE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE; UNINDEXED DRUG;

ARTICLE; BLEEDING DISORDER; CARDIOTOXICITY; DRUG CONTRAINDICATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; GENERAL PRACTICE; GERMANY; HEART FAILURE; HUMAN; HYPERICUM PERFORATUM; HYPOKALEMIA; MUSCLE DISEASE; PATIENT COMPLIANCE; PATIENT SAFETY; PHARMACEUTICAL CARE; PHARMACODYNAMICS; POLYPHARMACY; PRESCRIPTION; QT PROLONGATION; RETROSPECTIVE STUDY; VASOCONSTRICTION;

EID: 33750860774     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44539     Document Type: Article

References (57)

1. Ansari SR, Chopra N. Gatifloxacin and prolonged QT interval. Am J Med Sci. 2004; 327: 55-56.
2. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ, Shea BF. Hallisey R et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995; 274: 29-34.
3. Bates DW, Teich JM, Lee J, Seger D, Kuperman GJ, Ma'Luf N, Boyle D, Leape L. The impact of computerized physician order entry on medication error prevention. J Am Med Inform Assoc. 1999; 6: 313-321.
4. Bergk V, Gasse C, Schnell R, Haefeli WE. Requirements for a successful implementation of drug interaction information systems in general practice: results of a questionnaire survey in Germany. Eur J Clin Pharmacol. 2004; 60: 595-602.
5. Boyd RA, Stern RH, Stewart BH, Wa X, Reyner EL, Zegarac EA, Randinitis EJ, Whitfield L. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol. 2000; 40: 91-98.
6. Buurma H, de Smet PA, Leufkens HG, Egberts AC. Evaluation of the clinical value of pharmacists' modifications of prescription errors. Br J Clin Pharmacol. 2004; 58. 503-511.
7. de Wazieres B, Carol C, Vernaz J, Ledesert B, Le Pape A, Jeandel C, Fourcade J. Study of drug prescribing in patients older than 65 in Languedoc-Roussillon. Rev Med Interne. 2002; 23: 745-750.
8. Debruyne D, Commeau P, Grollier G, Huret B, Scanu P, Moulin M. Nicardipine does not significantly affect serum digoxin concentrations at the steady state of patients with congestive heart failure. Int J Clin Pharmacol Res. 1989; 9: 15-19.
9. Dunselman PH, Scaf AH, Kuntze CE, Lie KI, Wesseling H. Digoxin-felodipme interaction in patients with congestive heart failure. Eur J Clin Pharmacol. 1988; 35: 461-465.
10. Geppert U, Beindl W, Hawranek T, Hintner H. Drug interactions in clinical practice. A pilot project for quality assurance in prescribing. Hautarzt. 2003; 54: 53-57.
11. Glassman PA, Simon B, Belperio P, Lanto A. Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care. 2002; 40: 1161-1171.
12. Glassman PA, Belperio P, Simon B, Lanto A, Lee M. Exposure to automated drug alerts over time: effects on clinicians' knowledge and perceptions. Med Care. 2006; 44: 250-256.
13. Gomberg-Maitland M, Baran DA, Faster V. Treatment of congestive heart failure: guidelines for the primary care physician and the heart failure specialist. Arch Intern Med. 2001; 161: 342-352.
14. Grahame-Smith DG, Aronson JK. Clinical pharmacology and drug therapy. Oxford: Oxford University Press; 2002.
15. Hach I, Rentsch A, Krappweis J, Kirch W. Psychopharmaceutical prescriptions to older people. A comparison between patients in aged- and nursing homes, out-patient treatment with nursing care and outpatients without nursing care. Z Gerontol Geriatr. 2004; 37: 214-220.
16. Haefeli WE. Individualized drug therapy - need for improvement. Ther Umsch. 2000; 57: 545-546.
17. Halkin H, Katzir I, Kurman I, Jan J, Malkin BB. Preventing drug interactions by online prescription screening in community pharmacies and medical practices. Clin Pharmacol Ther. 2001; 69: 260-265.
18. Hamilton RA, Briceland LL, Andritz MH. Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population. Pharmacotherapy. 1998; 18: 1112-1120.
19. Hebert MF Park JM, Chen YL, Akhtar S, Larson AM. Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol. 2004; 44: 89-94.
20. Hedman A, Angelin B, Arvidsson A, Beck O, Dahlqvist R, Nilsson B, Olsson M, Schenck-Gustafsson K. Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. Clin Pharmacol Ther. 1991; 49: 256-262.
21. Ho G, Tierney MG, Dales RE. Evaluation of the effect of norfloxacin on the pharmacokinetics of theophylline. Clin Pharmacol Ther. 1988; 44: 35-38.
22. Hoppe UC, Böhm M, Dietz R, Hanrath P, Kroemer HK, Osterspey A, Schmaltz AA, Erdmann E. Leitlimen zur Therapie der chronischen Herzinsuffizienz. Z Kardiol. 2005; 94: 488-509.
23. Jankel CA, Fitterman LK. Epidemiology ofdrug-drug interactions as a cause of hospital admissions. Drug Saf. 1993; 9: 51-59.
24. Johne A, Sehmider J, Brockmöller J, Stadelmann AM, Stormer E, Bauer S, Schöller G, Langheinrich M, Roots I. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum). J Clin Psychopharmacol. 2002; 22: 46-54.
25. Jorens PG, van den Heuvel PA, Ranquin RE, van den Branden FA, Parizel GA. Amiodarone induced torsades de pointe. Report of three cases and review of literature. Acta Cardiol. 1989; 44: 411-421.
26. June RA, Nasr I. Torsades de pointes with terfenadine ingestion. Am J Emerg Med. 1997; 15: 542-543.
27. Juurlink DN, Mamdani M, Kopp A, Lautiacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003; 289: 1652-1658.
28. Kantola T, Kivistö KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther. 1998; 64: 177-182.
29. Karliova M, Treichel U, Malago M, Frilling A, Gerken G, Broelsch CE. Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol. 2000; 33: 853-855.
30. Kewitz H. Surveillance of drug therapy in the hospital. Verh Dtsch Ges Inn Med. 1977; 83: 1487-1502.
31. Kindermann M, Janzen I, Hennen B, Bohm M. Chronic heart failure - treatment. Dtsch Med Wochenschr. 2002; 127: 1139-1144.
32. Köhler GI, Bode-Böger SM, Busse R, Hoolimann M, Welte T, Böger RH. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther. 2000; 38: 504-513.
33. Lantz MS, Buchalter E, Giambanco V. St. John's wort and antidepressant drug interactions in the elderly J Geriatr Psychiatry Neurol. 1999; 12: 7-10.
34. Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA, Hebert L, Newhouse JP, Weiler PC, Hiatt H. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N EngI J Med. 1991; 324: 377-384.
35. Lehmann HU, Witt E, Temmen L, Hochrein H. Life-threatening digitalis intoxication with and without additional diuretic treatment (author's transl). Dtsch Med Wochenschr. 1978; 103: 1566-1571.
36. Lewis M, Lowel H, Stieber J, Engelbrecht R, Hormann A, John J. Drug interactions in the prescriptions of patients before and after a heart infarct: results of the MONICA Augsburg heart infarct registry. Soz Präventivmed. 1991; 36: 9-17.
37. Linnarsson R. Drug interactions in primary healthcare. A retrospective database study and its implications for the design ofa computerized decision support system. Scand J Prim Health Care. 1993; 11: 181-186.
38. Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T. QT prolongation and torsades de pointes after administration of trimethoprim-sulfa-methoxazole. Am J Cardiol. 1987; 59: 376-377.
39. Magnus D, Rodgers S, Avery AJ. GPs' views on computerized drug interaction alerts: questionnaire survey. J Clin Pharm Ther. 2002; 27: 377-382.
40. Marcus FI. Drug interactions with amiodarone. Am Heart J. 1983; 106: 924-930.
41. May FE, Stewart PB, Cluff LE. Drug interactions and multiple drug administration. Clin Pharmacol Ther. 1977; 22: 322-328.
42. Merlo J, Liedholm H, Lindblad U, Bjorck-Linne A, Falt J, Lindberg G, Melander A. Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999: cross sectional study. BMJ. 2001; 323: 427-428.
43. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004; 329: 15-19.
44. Platt D. Multimorbidity and pharmacotherapy in the elderly. Internist (Berl). 1991; 32: 460-466.
45. Rapke C, Hofmann G, Stedtfeld HW, Scherbel G. Cooperation between physician and pharmacist to determine and resolve errors in concomitant medication previously prescribed for trauma patients. Quality assurance study. Unfallchirurg. 2004; 107: 1041-1049.
46. Robson RA, Begg EJ, Atkinson HC, Saunders DA, Frampton CM. Comparative effects of ciprofloxacin and lomefloxacin on the oxidative metabolism of theophylline. Br J Clin Pharmacol. 1990; 29: 491-493.
47. Rosholm JU, Bjerrum L, Hallas J, Worm J, Gram LF. Polypharmacy and the risk of drug-drug interactions among Danish elderly. A prescription database study. Dan Med Bull. 1998; 45: 210-213.
48. Schwabe U, Paffrath D. Arzneiverordnungs-Report 2005. Heidelberg: Springer Medizin Verlag; 2006.
49. Schwartz JB, Migliore PJ. Effect of nifedipine on serum digoxin concentration and renal digoxin clearance. Clin Pharmacol Ther. 1984; 36: 19-24.
50. Schwartz JB. Effects of amlodipine on steady-state digoxin concentrations and renal digoxin clearance. J Cardiovasc Pharmacol. 1988; 12: 1-5.
51. Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging. 1998; 12: 485-494.
52. Stanton LA, Peterson GM, Rumble RH, Cooper GM, Polack AE. Drug-related admissions to an Australian hospital. J Clin Pharm Ther. 1994; 19: 341-347.
53. Steven ID, Malpass A, Moller J, Runciman WB, Helps SC. Towards safer drug use in general practice. J Qual Clin Pract. 1999; 19: 47-50.
54. Swanson JR, Jones GR, Krasselt W, Denmark LN, Ratti F. Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: a review of the literature and possible mechanisms. J Forensic Sci. 1997; 42: 335-339.
55. Verschraagen M, Koks CH, Schellens JH, Beijnen JH. P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol, Res. 1999; 40: 301-306.
56. Wang E, Casciano CN, Clement RP, Johnson WW. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res. 2001; 18: 800-806.
57. Weber E, Sehrt U. Drug interactions III. Münchn Med Wochenschr. 1979; 121: 25-27.